Faithful readers of the Center for Individualized Medicine blog will remember when a little more than a month ago, we posted the Pharmacogenomics Primer. In the primer, we mention there’s a mantra here in the Pharmacogenomics Program: the right drug, at the right dose, at the right time.
Now, we can just call it the RIGHT Protocol. And the word is spreading.
Celebrating its 25th anniversary, the American College of Medical Genetics and Genomics (ACMG) gave top honors to a Mayo Clinic poster at its 2016 Annual Clinical Genetics Meeting. The poster was titled, “Participant Understanding of CYP2D6 Genetic Test Results and Attitudes Toward Pharmacogenomics: Mayo Clinic RIGHT Protocol”
RIGHT, of course, stands for Right Drug, Right Dose, Right Time. That mantra again.
Janet Olson, Ph.D., and her colleagues, wanted to examine the predictors of patient understanding of CYP2D6 pharmacogenomic test results and to identify key features required to improve future educational efforts of pharmacogenomic testing.
CYP2D6, which stands for cytochrome P450 2D6, is one of the most important enzymes involved in drug metabolism. It is responsible for the breakdown of nearly a quarter of all medicines prescribed.
“Despite our attempts to simplify the results,” Dr. Olson said, “we found that over a third of the people didderstand the pharmacogenomics test results. In the future, when we present the test results to a person, we need to do a better job of explaining the results with good examples and we need to custom tailor the results to the individual.”
Here is the abstract from the poster that Dr. Olson is presenting this week at the 2016 ACMG Annual Clinical Genetics Meeting.
The Right Drug, Right Dose, Right Time – Using Genomic Data to Individualize Treatment (RIGHT) protocol tests the concept that DNA sequence information can be coupled to the electronic medical record (EMR) for use in health care. The study is designed to integrate prescription drug-related genetic information in the EMR and make it readily available for health care providers to access and use when prescribing certain drugs.
Genetic variants play a role in how an individual responds to certain prescription drugs. Knowledge about these genetic variants can be used by health care providers to determine which drug is best for an individual and at what dose. By testing for gene variants in a person’s DNA, researchers are better able to determine if an individual needs a lower or higher dose of a prescription drug, if that person is at increased risk of side effects, or if he or she could experience life-threatening reactions.
This information can result in the right drug, at the right dose, at the right time — dramatically improving drug efficacy and patient safety.
American College of Medical Genetics and Genomics
The American College of Medical Genetics and Genomics (ACMG) is an organization composed of biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic counselors and other health care professionals committed to the practice of medical genetics. It advocates translating genetic discoveries into better patient care and establishing best practices in genetic and genomic medicine.
The ACMG Annual Clinical Genetics Meeting provides genetics professionals with the opportunity to learn how genetics and genomics are being integrated into medical or clinical practice. The annual meeting will present the latest developments and research in clinical genetics and genomics.